ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

ORI finds Hopkins Coordinator Falsified Information On Grant

May 16, 1997

Seffrin, Thomas Lead List of ACS Exec. VP Candidates, Reportedly

May 1, 1992

In Brief: OSCC Staff Appointments Announced Report Available On Chemical Disposal Health Aspects

August 3, 1984

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

December 5, 2014

NCI To Fund 22 Of 38 Clinical Investigator Applications, Five Of Them To Surgeons

June 1, 1984

Emory Executive Objects to Report On Merit review

July 22, 1977